Antibody–Drug Conjugates (ADCs) and Their Journey to Autoimmune Disease Immunotherapy

Antibody–drug conjugates (ADCs) represent a novel and rapidly evolving class of targeted therapeutics that combine the high specificity of monoclonal antibodies (mAbs) with the potent cytotoxic effects of small-molecule drugs.

Institutions

Publication Details

Published
2025-12-11
DOI
https://doi.org/10.3390/msf2025040002
Primary Topic
HER2/EGFR in Cancer Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Antibody–Drug Conjugates (ADCs) and Their Journey to Autoimmune Disease Immunotherapy

HER2/EGFR in Cancer Research
article

Antibody–Drug Conjugates (ADCs) and Their Journey to Autoimmune Disease Immunotherapy

article en

Abstract

Antibody–drug conjugates (ADCs) represent a novel and rapidly evolving class of targeted therapeutics that combine the high specificity of monoclonal antibodies (mAbs) with the potent cytotoxic effects of small-molecule drugs.

University of the West Indies (TT)
Good health and well-being
Openalex Percentile: Top 32%
HER2/EGFR in Cancer Research
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Antibody–Drug Conjugates (ADCs) and Their Journey to Autoimmune Disease Immunotherapy · (2025) | TGRS Research Map | TGRS